{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:06:31Z","timestamp":1790798791084,"version":"4.1.0"},"reference-count":91,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: Systemic and tissue inflammation play a crucial role in the pathophysiology of cardiometabolic disorders. Presepsin is a newly discovered marker of acute phase inflammation that is produced by monocytes or macrophages in response to bacterial infection and is a soluble fraction of the lipopolysaccharide (LPS) receptor. LPS is an endotoxin that, through the breakdown of the intestinal barrier, penetrates the systemic circulation and is an important bacterial mediator in the pathogenesis of sepsis and septic shock. Methods: A narrative review of the existing literature. Results: A growing body of evidence demonstrates that intestinal dysbiosis is involved in the pathogenesis of diabetes mellitus (DM) and cardiovascular (CV) disease, leading to increased circulating LPS concentrations in people with cardiometabolic disorders, even in the absence of infection. These data provide the theoretical background for a link between presepsin, DM, and CV pathology. Preliminary studies suggest that presepsin levels are downregulated in patients with well-controlled type 2 DM and correlate with continuous glucose monitoring metrics in infection-free individuals with type 1 DM. However, prospective data on the association between presepsin and the risk of diabetic complications are currently lacking. Presepsin has also been found to be elevated in infection-free individuals with myocardial infarction, heart failure, and myocarditis compared to controls and has been shown to correlate with mortality risk in subjects at high CV risk. Conclusions: The clinical utility of presepsin in the monitoring of patients with cardiometabolic disorders warrants further investigation by future studies.<\/jats:p>","DOI":"10.3390\/jpm15040125","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T05:35:03Z","timestamp":1742880903000},"page":"125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Presepsin: An Emerging Biomarker in the Management of Cardiometabolic Disorders"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7732-709X","authenticated-orcid":false,"given":"Dimitrios","family":"Kouroupis","sequence":"first","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Zografou","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Doukelis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-684X","authenticated-orcid":false,"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5713","authenticated-orcid":false,"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Aristotle University of Thessaloniki, Hippokration General Hospital, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-2504","authenticated-orcid":false,"given":"Athina","family":"Pyrpasopoulou","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5549-7048","authenticated-orcid":false,"given":"Konstantinos","family":"Stavropoulos","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9643-9066","authenticated-orcid":false,"given":"Christodoulos","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Third Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Giouleme","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Gastroenterology and Hepatology Division, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2376-740X","authenticated-orcid":false,"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Diabetes Centre, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Doumas","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1352","authenticated-orcid":false,"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990\u20132022","volume":"82","author":"Mensah","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"DeGroat, W., Abdelhalim, H., Patel, K., Mendhe, D., Zeeshan, S., and Ahmed, Z. (2024). Discovering biomarkers associated and predicting cardiovascular disease with high accuracy using a novel nexus of machine learning techniques for precision medicine. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-50600-8"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","article-title":"The burden and risks of emerging complications of diabetes mellitus","volume":"18","author":"Tomic","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","article-title":"Global trends in diabetes complications: A review of current evidence","volume":"62","author":"Harding","year":"2019","journal-title":"Diabetologia"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"The DCCT Research Group (1987). Diabetes Control and Complications Trial (DCCT): Results of feasibility study. Diabetes Care, 10, 1\u201319.","DOI":"10.2337\/diacare.10.1.1"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group (1991). UKProspective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia, 34, 877\u2013890.","DOI":"10.1007\/BF00400195"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00592-020-01574-w","article-title":"Alternative methods for assessing glycemia might prove useful in cases of discordance between glycated hemoglobin and self-monitoring of blood glucose","volume":"57","author":"Koufakis","year":"2020","journal-title":"Acta Diabetol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155791","DOI":"10.1016\/j.metabol.2024.155791","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on continuous glucose monitoring metrics, as adjunctive to insulin in adults with type 1 diabetes mellitus: A meta-analysis of randomized controlled trials","volume":"153","author":"Popovic","year":"2024","journal-title":"Metabolism"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1111\/dom.15979","article-title":"Effects of glucagon-like peptide-1 receptor agonists on glycated haemoglobin and continuous glucose monitoring metrics as adjunctive therapy to insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/19322968211070855","article-title":"The Benefits of Utilizing Continuous Glucose Monitoring of Diabetes Mellitus in Primary Care: A Systematic Review","volume":"17","author":"Kieu","year":"2023","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e002573","DOI":"10.1136\/bmjdrc-2021-002573","article-title":"Time in range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes: A systematic review","volume":"210","author":"Raj","year":"2022","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/dia.2016.0011","article-title":"Limitations of Continuous Glucose Monitor Usage","volume":"18","author":"Anhalt","year":"2016","journal-title":"Diabetes Technol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13231","DOI":"10.1111\/obr.13231","article-title":"The role of autoimmunity in the pathophysiology of type 2 diabetes: Looking at the other side of the moon","volume":"22","author":"Koufakis","year":"2021","journal-title":"Obes. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5076858","DOI":"10.1155\/2020\/5076858","article-title":"Elevated Serum TNF-\u03b1 Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance","volume":"2020","author":"Alzamil","year":"2020","journal-title":"J. Obes."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.15420\/ecr.2018.33.1","article-title":"The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives","volume":"14","author":"Tsalamandris","year":"2019","journal-title":"Eur. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000515740","article-title":"Intracellular and Extracellular Lipopolysaccharide Signaling in Sepsis: Avenues for Novel Therapeutic Strategies","volume":"13","author":"Gabarin","year":"2021","journal-title":"J. Innate Immun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/imm.13002","article-title":"Properties and functions of adipose tissue macrophages in obesity","volume":"155","author":"Russo","year":"2018","journal-title":"Immunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/obr.12370","article-title":"Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: Implications for inflammation and obesity","volume":"17","author":"Hersoug","year":"2016","journal-title":"Obes. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Qin, X., and Zou, H. (2022). The role of lipopolysaccharides in diabetic retinopathy. BMC Ophthalmol., 22.","DOI":"10.1186\/s12886-022-02296-z"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13098-018-0360-3","article-title":"Markers of metabolic endotoxemia as related to metabolic syndrome in an elderly male population at high cardiovascular risk: A cross-sectional study","volume":"10","author":"Awoyemi","year":"2018","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.2337\/dc13-0451","article-title":"Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity: Evidence from bariatric surgery","volume":"36","author":"Nestvold","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/1440-1681.13250","article-title":"Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics","volume":"47","author":"Moludi","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/dc12-0702","article-title":"Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis","volume":"36","author":"Wang","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00125-009-1338-3","article-title":"Association of C-reactive protein with type 2 diabetes: Prospective analysis and meta-analysis","volume":"52","author":"Lee","year":"2009","journal-title":"Diabetologia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/qjmed\/hcg134","article-title":"C-reactive protein and cardiovascular disease: New insights from an old molecule","volume":"96","author":"Hirschfield","year":"2003","journal-title":"QJM"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1210\/jc.2010-0305","article-title":"Plasma procalcitonin is associated with obesity, insulin resistance, and the metabolic syndrome","volume":"95","author":"Abbasi","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","first-page":"e18357","article-title":"Procalcitonin Correlates with Cardiovascular Risk Better Than Highly Sensitive C-Reactive Protein in Patients with Type 2 Diabetes in Sub-Saharan Africa: Results From a Cross-Sectional Study","volume":"13","author":"Katte","year":"2021","journal-title":"Cureus"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1007\/s00125-011-2216-3","article-title":"Plasma procalcitonin and risk of type 2 diabetes in the general population","volume":"54","author":"Abbasi","year":"2011","journal-title":"Diabetologia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejim.2014.12.009","article-title":"Procalcitonin and long-term prognosis after an admission for acute heart failure","volume":"26","author":"Villanueva","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijcard.2014.08.106","article-title":"Determinants of procalcitonin concentration in acute heart failure","volume":"177","author":"Mollar","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"H1817","DOI":"10.1152\/ajpheart.00472.2008","article-title":"Human neutrophil peptides: A novel potential mediator of inflammatory cardiovascular diseases","volume":"295","author":"Quinn","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/0735-1097(95)00578-1","article-title":"An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion","volume":"27","author":"Arai","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11324","DOI":"10.3390\/ijms150711324","article-title":"Endothelial dysfunction in chronic inflammatory diseases","volume":"15","author":"Steyers","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijcard.2011.06.112","article-title":"Anti-tumor necrosis factor \u03b1 treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis","volume":"151","author":"Avgerinou","year":"2011","journal-title":"Int. J. Cardiol."},{"key":"ref_39","first-page":"e45483","article-title":"Inflammation in Cardiovascular Disease: A Comprehensive Review of Biomarkers and Therapeutic Targets","volume":"15","author":"Gupta","year":"2023","journal-title":"Cureus"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Bochaton, T., Lassus, J., Paccalet, A., Derimay, F., Rioufol, G., Prieur, C., Bonnefoy-Cudraz, E., Crola Da Silva, C., Bernelin, H., and Amaz, C. (2021). Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245684"},{"key":"ref_41","first-page":"99","article-title":"Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease","volume":"40","author":"Guarner","year":"2015","journal-title":"Interdiscip. Top. Gerontol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.archger.2017.08.007","article-title":"Circulating interleukin-6 levels and cardiovascular and all-cause mortality in the elderly population: A meta-analysis","volume":"73","author":"Li","year":"2017","journal-title":"Arch. Gerontol. Geriatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1076029613494469","article-title":"The role of the nonspecific inflammatory markers in determining the anatomic extent of venous thromboembolism","volume":"21","author":"Bakirci","year":"2015","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, X., Li, J., and Wu, G. (2021). Relationship of Neutrophil-to-Lymphocyte Ratio with Carotid Plaque Vulnerability and Occurrence of Vulnerable Carotid Plaque in Patients with Acute Ischemic Stroke. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/6894623"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Perrone, M.A., Aimo, A., Bernardini, S., and Clerico, A. (2023). Inflammageing and Cardiovascular System: Focus on Cardiokines and Cardiac-Specific Biomarkers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010844"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Lin, G., Dai, C., Xu, K., and Wu, M. (2021). Predictive value of neutrophil to lymphocyte ratio and red cell distribution width on death for ST segment elevation myocardial infarction. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-91082-w"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2019.03.001","article-title":"Biomarker assessment for early infarct size estimation in ST-elevation myocardial infarction","volume":"64","author":"Tiller","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchf.2013.11.006","article-title":"Anti-inflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study","volume":"2","author":"Deftereos","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","article-title":"Colchicine and the heart: Pushing the envelope","volume":"62","author":"Deftereos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kyriazopoulou, E., Leventogiannis, K., Tavoulareas, G., Mainas, E., Toutouzas, K., Mathas, C., Prekates, A., Sakka, V., Panagopoulos, P., and Syrigos, K. (2023). Presepsin as a diagnostic and prognostic biomarker of severe bacterial infections and COVID-19. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-30807-5"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Dr\u0103goescu, A.N., P\u0103dureanu, V., St\u0103nculescu, A.D., Chiu\u021bu, L.C., Florescu, D.N., Gheonea, I.A., P\u0103dureanu, R., Stepan, A., Streba, C.T., and Droca\u0219, A.I. (2020). Presepsin as a Potential Prognostic Marker for Sepsis According to Actual Practice Guidelines. J. Pers. Med., 11.","DOI":"10.3390\/jpm11010002"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Piccioni, A., Santoro, M.C., de Cunzo, T., Tullo, G., Cicchinelli, S., Saviano, A., Valletta, F., Pascale, M.M., Candelli, M., and Covino, M. (2021). Presepsin as Early Marker of Sepsis in Emergency Department: A Narrative Review. Medicina, 57.","DOI":"10.3390\/medicina57080770"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"64","DOI":"10.11613\/BM.2015.007","article-title":"Determination of reference interval for presepsin, an early marker for sepsis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10156-005-0400-4","article-title":"Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis","volume":"11","author":"Yaegashi","year":"2005","journal-title":"J. Infect. Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Lee, S., Song, J., Park, D.W., Seok, H., Ahn, S., Kim, J., Park, J., Cho, H.J., and Moon, S. (2022). Diagnostic and prognostic value of presepsin and procalcitonin in non-infectious organ failure, sepsis, and septic shock: A prospective observational study according to the Sepsis-3 definitions. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-021-07012-8"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Koizumi, Y., Sakanashi, D., Mohri, T., Watanabe, H., Shiota, A., Asai, N., Kato, H., Hagihara, M., Murotani, K., and Yamagishi, Y. (2020). Can presepsin uniformly respond to various pathogens?\u2014An in vitro assay of new sepsis marker. BMC Immunol., 21.","DOI":"10.1186\/s12865-020-00362-z"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.4049\/jimmunol.172.7.4470","article-title":"CD14 is an acute-phase protein","volume":"172","author":"Bas","year":"2004","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Miyoshi, M., Inoue, Y., Nishioka, M., Ikegame, A., Nakao, T., Kishi, S., Doi, T., and Nagai, K. (2019). Clinical evaluation of presepsin considering renal function. PLoS ONE, 14.","DOI":"10.1101\/604991"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2013.09.019","article-title":"Presepsin (sCD14-ST) in emergency department: The need for adapted threshold values?","volume":"427","author":"Trabattoni","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4103\/joacp.joacp_560_21","article-title":"Comparison between presepsin, procalcitonin, and CRP as biomarkers to diagnose sepsis in critically ill patients","volume":"39","author":"Juneja","year":"2023","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Yoon, S.H., Kim, E.H., Kim, H.Y., and Ahn, J.G. (2019). Presepsin as a diagnostic marker of sepsis in children and adolescents: A systemic review and meta-analysis. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4397-1"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ha, E.Y., Park, I.R., Chung, S.M., Roh, Y.N., Park, C.H., Kim, T.G., Kim, W., and Moon, J.S. (2024). The Potential Role of Presepsin in Predicting Severe Infection in Patients with Diabetic Foot Ulcers. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082311"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5312\/wjo.v14.i7.547","article-title":"Physiologic postoperative presepsin kinetics following primary cementless total hip arthroplasty: A prospective observational study","volume":"14","author":"Bizzoca","year":"2023","journal-title":"World J. Orthop."},{"key":"ref_64","first-page":"2057","article-title":"Presepsin as a Biomarker for Sepsis Evolutions in Diabetis","volume":"66","author":"Botnariu","year":"2015","journal-title":"Rev. Chim."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Kouroupis, D., Zografou, I., Balaska, A., Reklou, A., Varouktsi, A., Paschala, A., Pyrpasopoulou, A., Stavropoulos, K., Vogiatzis, K., and Sarvani, A. (2024). Presepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory Study. Biomedicines, 12.","DOI":"10.3390\/biomedicines12091960"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.metabol.2016.12.009","article-title":"Metabolic endotoxemia and diabetes mellitus: A systematic review","volume":"68","author":"Gomes","year":"2017","journal-title":"Metabolism"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tem.2022.10.002","article-title":"Can sodium-glucose cotransporter 2 inhibitors \u2018spin the thread of life\u2019?","volume":"34","author":"Maltese","year":"2023","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s11096-021-01256-9","article-title":"Sodium-glucose co-transporter 2 inhibitors in COVID-19: Meeting at the crossroads between heart, diabetes and infectious diseases","volume":"43","author":"Koufakis","year":"2012","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mce.2008.09.030","article-title":"Insulin exhibits short-term anti-inflammatory but long-term proinflammatory effects in vitro","volume":"298","author":"Iwasaki","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Koufakis, T., Kouroupis, D., Dimakopoulos, G., Georgiadis, T., Kourti, A., Doukelis, P., Zografou, I., Patoulias, D., Popovic, D.S., and Pyrpasopoulou, A. (2025). Obesity, but Not Overweight, Is Associated with Increased Presepsin Levels in Infection-Free Individuals: An Exploratory Study. Biomedicines, 13.","DOI":"10.3390\/biomedicines13030701"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zografou, I., Kouroupis, D., Dimakopoulos, G., Doukelis, P., Doumas, M., and Koufakis, T. (2024). Correlation Between Presepsin Levels and Continuous Glucose Monitoring Metrics in Infection-Free Individuals with Type 1 Diabetes. J. Diabetes Sci. Technol., 19322968241288865.","DOI":"10.1177\/19322968241288865"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1177\/19322968221085273","article-title":"A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings","volume":"17","author":"Klonoff","year":"2023","journal-title":"J. Diabetes Sci. Technol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8954718","DOI":"10.1155\/2018\/8954718","article-title":"Serum Presepsin Levels Are Not Elevated in Patients with Controlled Hypertension","volume":"2018","author":"Biyik","year":"2018","journal-title":"Int. J. Hypertens."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.2174\/138161212802481282","article-title":"Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation","volume":"18","author":"Tuttolomondo","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Cavero-Redondo, I., Saz-Lara, A., Garc\u00eda-Ortiz, L., Lugones-S\u00e1nchez, C., Notario-Pacheco, B., Martinez-Vizcaino, V., and Gomez-Marcos, M.A. (2021). Comparative Effect of Antihypertensive Drugs in Improving Arterial Stiffness in Hypertensive Adults (RIGIPREV Study). A Protocol for Network Meta-Analysis. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph182413353"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1097\/CCM.0000000000003764","article-title":"Presepsin As a Biomarker for Evaluating Prognosis and Early Innate Immune Response of Out-of-Hospital Cardiac Arrest Patients After Return of Spontaneous Circulation","volume":"47","author":"Qi","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/EJA.0000000000001243","article-title":"Presepsin for pre-operative prediction of major adverse cardiovascular events in coronary heart disease patients undergoing noncardiac surgery: Post hoc analysis of the Leukocytes and Cardiovascular Peri-operative Events-2 (LeukoCAPE-2) Study","volume":"37","author":"Handke","year":"2020","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1213\/ANE.0000000000003738","article-title":"Elevated Presepsin Is Associated with Perioperative Major Adverse Cardiovascular and Cerebrovascular Complications in Elevated-Risk Patients Undergoing Noncardiac Surgery: The Leukocytes and Cardiovascular Perioperative Events Study","volume":"128","author":"Handke","year":"2019","journal-title":"Anesth. Analg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.15511\/ejcm.18.00260","article-title":"Serum Presepsin Levels in Patients with Decompensated Heart Failure","volume":"6","author":"Karabulut","year":"2018","journal-title":"J. Updates Cardiovasc. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.cardfail.2017.08.296","article-title":"Presepsin, Soluble CD14 Subtype, Is a Novel Marker of Short-term Mortality in Patients Hospitalized for Worsening Heart Failure","volume":"23","author":"Nishimura","year":"2017","journal-title":"J. Card. Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"ehaa946.1838","DOI":"10.1093\/ehjci\/ehaa946.1838","article-title":"Circulating presepsin (soluble CD14 subtype) as a novel marker of mortality in patients treated at medical cardiac intensive care units","volume":"41","author":"Ishii","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e20230017","DOI":"10.36660\/abc.20230017","article-title":"Could Zonulin and Presepsin Be Biomarkers and Therapeutic Targets for Acute Myocarditis?","volume":"120","author":"Toprak","year":"2023","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.5114\/amsad.2017.66827","article-title":"Presepsin (sCD14-ST): Could it be a novel marker for the diagnosis of ST elevation myocardial infarction?","volume":"2","author":"Caglar","year":"2017","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"ref_85","first-page":"A11016","article-title":"Abstract 11016: Combined Assessment of Presepsin, Soluble CD14 Subtype, and B-Type Natriuretic Peptide Predicts Cardiovascular Events in Outpatients with Chronic Kidney Disease","volume":"138","author":"Nishimura","year":"2018","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/hr.2011.6","article-title":"Are blood pressure and diabetes additive or synergistic risk factors? Outcome in 8494 subjects randomly recruited from 10 populations","volume":"34","author":"Sehestedt","year":"2011","journal-title":"Hypertens Res."},{"key":"ref_87","unstructured":"Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation (2024, December 01). Emerging Safety Science: Workshop Summary, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK4041\/."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Filipovic, M.G., and Luedi, M.M. (2023). Cardiovascular Biomarkers: Current Status and Future Directions. Cells, 12.","DOI":"10.3390\/cells12222647"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Calder\u00f3n, P., Wiedemann, L., and Ben\u00edtez-P\u00e1ez, A. (2022). The microbiota composition drives personalized nutrition: Gut microbes as predictive biomarkers for the success of weight loss diets. Front. Nutr., 9.","DOI":"10.3389\/fnut.2022.1006747"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s13258-024-01491-0","article-title":"The effect of canagliflozin on gut microbiota and metabolites in type 2 diabetic mice","volume":"46","author":"Zeng","year":"2024","journal-title":"Genes. Genom."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/4\/125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:59:35Z","timestamp":1760029175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/4\/125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":91,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jpm15040125"],"URL":"https:\/\/doi.org\/10.3390\/jpm15040125","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}